- Eyenovia Inc EYEN announced results from a research study that evaluated the gene and protein expression of cytokines and chemokines after latanoprost+benzalkonium chloride (BAK) treatment administered via Optejet versus latanoprost+BAK administered via standard eye drops.
- Preservatives are used to support product sterility and prolong shelf-life. But patients treated with BAK preserved glaucoma medications often suffer inflammatory side effects.
- Related: HC Wainwright Initiates This Eye-Focused Stock With Almost 400% Upside.
- The study found that the expression of proinflammatory cytokines and chemokines was decreased in two out of three cytokines with the latanoprost+BAK treatment administered via Optejet technology compared to latanoprost+BAK administered via standard drops.
- In these early findings, the Optejet technology appears better than latanoprost+BAK administered via standard drops in reducing inflammatory processes and pathways.
- Eyenovia’s Optejet microdose formulation and delivery platform for ocular therapeutics use high-precision piezo-print technology to deliver 6-8 μL of a drug, consistent with the capacity of the tear film of the eye.
- Eyenovia estimates the volume of ophthalmic solution administered with the Optejet is less than 20% of that delivered using conventional eyedroppers, thus reducing overdosing and exposure to drugs and preservatives.
- Price Action: EYEN shares are up 11.70% at $2.10 on the last check Thursday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.